Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Dazucorilant in Hepatic Impairment
NCT06928779Phase 1Completed
- Sponsor
- Corcept Therapeutics
- Start
- Oct 2024
- Primary completion
- Dec 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of dazucorilant in amyotrophic lateral sclerosis (ALS), sponsored by Corcept Therapeutics. Primary endpoints: Area under the concentration-time curve from time zero to the last non-zero concentration at 144 hours, Area under the concentration-time curve from time zero to infinity at 144 hours and 3 more. Started Oct 2024; status: completed.
02
Drugs
dazucorilant
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT06928779.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06928779.